Amgen News

Biotech drugmaker Amgen said Monday its board approved a new $5 billion stock buyback plan.

Amgen Inc. today announced results from three studies on the safety and efficacy of Nplate in adult patients with myelodysplastic syndromes .

Filed under: Newsletters , Amgen Inc , ETF Investing , Commodities , Oil , Agriculture , Stocks to Buy "Nothing has changed to unseat this liquidity-driven rally," says options expert Larry McMillan .

Teva Pharmaceutical has decided it's not worth waiting for the U.S. government to establish a pathway for approval of generic versions of biologic drugs.

November 29, 2009 Posted: November 27, 2009, 9:58 PM CST Last updated: November 27, 2009, 10:00 PM CST The allegations in the lawsuit are shocking.

Editor's Note: A version of this story appeared in the Business Journal's November 30 print edition.

The amended agreement gives Biovitrum exclusive rights to develop, manufacture, market and sell Kineret for these additional indications in rare diseases.

With a week left to match a challenge from the Amgen Foundation, a fund drive paying for basic needs of Ventura County residents has raised more than $130,000. The money is being given to The Buck Starts Here, a campaign aimed at helping local residents survive in a time of double-digit unemployment.

Managers in money management firm PRIMECAP Management Company prefer to stay behind the scene, focusing on money management and letting the other people to do the marketing for them.

In his article " The Market's 10 Best Stocks ," my colleague Tim Hanson pointed out the benefits of searching for the next multibagger success stories among the smallest of companies.

Drugmaker ImmunoGen Inc said it licensed its technology to develop anti-cancer drugs to Amgen Inc for a $1 million upfront payment.

Waltham biotechnology firm ImmunoGen Inc. has announced a second license granted to Amgen Inc.

ImmunoGen Inc. said Thursday that Amgen Inc. licensed rights to a second potential cancer-treatment from the company for $1 million upfront.

While the market has staged a nice comeback since the spring and the economy seems to be slowly righting itself, things are still rough out there.

Rule Breaker . As long as I live, I'll never forget the day I first heard those two words.

Keith Leonard, founder of Kythera Biopharmaceuticals Inc. in Calabasas, said his degrees in engineering, business and history helped him launch a biotechnology company, but the ultimate decision was determined by an emotional readiness and a broad work experience.

Over his 28 years, Burrill's clients have included Steve Jobs of Apple, Genentech, Amgen and Gilead Sciences.

Vectibix, a cancer drug made by Amgen , did not show statistically significant survival rates for patients in a study of its effectiveness against advanced colorectal cancer.

A lawsuit launched against Amgen Inc. on Oct. 30 raises important questions about what is accepted practice when it comes to manufacturing and administering certain drugs and whether the company encouraged the fraudulent sale of free drugs to increase their use.

IA could write this article the usual way -- byA showing you how to turn your thousands into millionsA through investments in solid, well-known companies.